129 related articles for article (PubMed ID: 38388076)
21. Thyroglobulin antibodies: Trend over time and clinical impact in differentiated thyroid carcinoma with and without radioiodine ablation.
Iglesias ML; Calabretta JM; Coggiola O; Califano I
Endocrinol Diabetes Nutr (Engl Ed); 2022 Nov; 69(9):702-708. PubMed ID: 36470645
[TBL] [Abstract][Full Text] [Related]
22. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer.
Kim HO; Lee K; Lee SM; Seo GH
JAMA Intern Med; 2020 Jan; 180(1):54-61. PubMed ID: 31633736
[TBL] [Abstract][Full Text] [Related]
23. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.
Slonimsky E; Tulchinsky M
Curr Pharm Des; 2020; 26(31):3812-3827. PubMed ID: 32503402
[TBL] [Abstract][Full Text] [Related]
24. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
[TBL] [Abstract][Full Text] [Related]
25. Combined BRAF
Campennì A; Ruggeri RM; Siracusa M; Pignata SA; Di Mauro F; Vento A; Trimarchi F; Baldari S
J Endocrinol Invest; 2018 Nov; 41(11):1283-1288. PubMed ID: 29549631
[TBL] [Abstract][Full Text] [Related]
26. Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.
Segkos K; Porter K; Senter L; Ringel MD; Nabhan FA
Horm Cancer; 2018 Dec; 9(6):433-439. PubMed ID: 30088223
[TBL] [Abstract][Full Text] [Related]
27. Survival benefit of postoperative radioiodine therapy among patients with intermediate-risk differentiated thyroid carcinoma.
Wang J; Mao Y; Li L; Liang J; Huang H; Lin W; Chen G; Wen J
Endocrine; 2024 May; ():. PubMed ID: 38809346
[TBL] [Abstract][Full Text] [Related]
28. Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.
Sung TY; Jeon MJ; Lee YH; Lee YM; Kwon H; Yoon JH; Chung KW; Kim WG; Song DE; Hong SJ
J Clin Endocrinol Metab; 2017 Mar; 102(3):793-800. PubMed ID: 27809646
[TBL] [Abstract][Full Text] [Related]
29. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
30. Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma.
Kim M; Han M; Jeon MJ; Kim WG; Kim IJ; Ryu JS; Kim WB; Shong YK; Kim TY; Kim BH
Clin Endocrinol (Oxf); 2019 Sep; 91(3):449-455. PubMed ID: 31102417
[TBL] [Abstract][Full Text] [Related]
31. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
32. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
33. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
34. Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature.
Estorch M; Mitjavila M; Muros MA; Caballero E;
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(3):195-203. PubMed ID: 30745131
[TBL] [Abstract][Full Text] [Related]
35. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
36. Pediatric Thyroid Cancer: Postoperative Classifications and Response to Initial Therapy as Prognostic Factors.
Lazar L; Lebenthal Y; Segal K; Steinmetz A; Strenov Y; Cohen M; Yaniv I; Yackobovitch-Gavan M; Phillip M
J Clin Endocrinol Metab; 2016 May; 101(5):1970-9. PubMed ID: 26930182
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
38. Shifting paradigms in the management of pediatric differentiated thyroid cancer from static to dynamic risk stratification: a step forward toward precision medicine.
Ajdari SE; Shafiei B; Motazedian M; Qutbi M; Esmaeilzadeh P; Asli IN; Javadi H; Assadi M
Nuklearmedizin; 2019 Jun; 58(3):249-257. PubMed ID: 31060081
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
Simões-Pereira J; Ferreira TC; Limbert E; Cavaco BM; Leite V
Thyroid; 2021 Oct; 31(10):1514-1522. PubMed ID: 34155923
[No Abstract] [Full Text] [Related]
40. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
